How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
暂无分享,去创建一个
[1] David Moher,et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. , 2015, Revista panamericana de salud publica = Pan American journal of public health.
[2] Daniel Carpenter,et al. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA , 2014 .
[3] John P A Ioannidis,et al. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. , 2014, JAMA.
[4] John P A Ioannidis,et al. Improving the drug development process: more not less randomized trials. , 2014, JAMA.
[5] Thomas Agoritsas,et al. How to use a subgroup analysis: users' guide to the medical literature. , 2014, JAMA.
[6] Christopher H. Schmid,et al. Characteristics of Networks of Interventions: A Description of a Database of 186 Published Networks , 2014, PloS one.
[7] David Moher,et al. Reducing waste from incomplete or unusable reports of biomedical research , 2014, The Lancet.
[8] Harlan M Krumholz,et al. Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.
[9] Iain Chalmers,et al. How to increase value and reduce waste when research priorities are set , 2014, The Lancet.
[10] R. Tibshirani,et al. Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.
[11] U. Dirnagl,et al. Biomedical research: increasing value, reducing waste , 2014, The Lancet.
[12] Rustam Al-Shahi Salman,et al. Increasing value and reducing waste in biomedical research regulation and management , 2014, The Lancet.
[13] Lisa Hartling,et al. Quality of reporting in systematic reviews of adverse events: systematic review , 2014, BMJ : British Medical Journal.
[14] Nhan Tran,et al. Republished research: Implementation research: what it is and how to do it , 2013, British Journal of Sports Medicine.
[15] T. J. Moore,et al. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008. , 2014, JAMA internal medicine.
[16] S. Goodman,et al. Raw data from clinical trials: within reach? , 2013, Trends in pharmacological sciences.
[17] Omar Hasan,et al. Doctors’ health: taking the lifecycle approach , 2013, BMJ.
[18] J. Ioannidis,et al. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales , 2013, Nature Reviews Rheumatology.
[19] Frank Pétavy,et al. Access to patient-level trial data--a boon to drug developers. , 2013, The New England journal of medicine.
[20] Beate Wieseler,et al. Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data , 2013, PLoS medicine.
[21] J. Ioannidis,et al. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study , 2015, British Journal of Sports Medicine.
[22] John P A Ioannidis,et al. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients , 2013, BMJ : British Medical Journal.
[23] Huseyin Naci,et al. Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. , 2013, Journal of clinical epidemiology.
[24] Participant-level data and the new frontier in trial transparency. , 2013, The New England journal of medicine.
[25] Tina Hernandez-Boussard,et al. Overlapping meta-analyses on the same topic: survey of published studies , 2013, BMJ.
[26] Nazmus Saquib,et al. Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study , 2013, BMJ.
[27] G. Alexander,et al. The Food and Drug Administration Amendments Act and postmarketing commitments. , 2013, JAMA.
[28] C. Gamble,et al. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias — An Updated Review , 2013, PloS one.
[29] John P. A. Ioannidis,et al. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review , 2013, European journal of clinical investigation.
[30] I. Tannock,et al. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] J. Ioannidis,et al. Bias in associations of emerging biomarkers with cardiovascular disease. , 2013, JAMA internal medicine.
[32] Joel Lexchin,et al. Surrogate outcomes in clinical trials: a cautionary tale. , 2013, JAMA internal medicine.
[33] L. Bero. Industry sponsorship and research outcome: a Cochrane review. , 2013, JAMA internal medicine.
[34] J. Ioannidis,et al. Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents. , 2013, Journal of clinical epidemiology.
[35] J. Ioannidis,et al. Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. , 2013, Journal of clinical epidemiology.
[36] Tom Jefferson,et al. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports , 2013, BMJ Open.
[37] J. Sterne,et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study , 2013, BMJ.
[38] J. Ioannidis. Mega-trials for blockbusters. , 2013, JAMA.
[39] David Moher,et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa , 2012, Systematic Reviews.
[40] T. Fleming,et al. Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.
[41] John P A Ioannidis,et al. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? , 2012, BMJ : British Medical Journal.
[42] John P A Ioannidis,et al. Empirical evaluation of very large treatment effects of medical interventions. , 2012, JAMA.
[43] Ethan M Balk,et al. Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials , 2012, Annals of Internal Medicine.
[44] J. Lexchin,et al. Pharmaceutical research and development: what do we get for all that money? , 2012, BMJ : British Medical Journal.
[45] J. Cylus,et al. Raising the bar for market authorisation of new drugs , 2012, BMJ : British Medical Journal.
[46] S. Wyke,et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.
[47] S. Doggrell. The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? , 2012, Expert opinion on pharmacotherapy.
[48] E. Gale. Post-marketing studies of new insulins: sales or science? , 2012, BMJ : British Medical Journal.
[49] Mark A Hlatky,et al. Editorial Repeat Revascularization Is a Faulty End Point for Clinical Trials Article See P 267 the Syntax Trial , 2022 .
[50] Tom Jefferson,et al. The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience , 2012, PLoS medicine.
[51] L. Trinquart,et al. Underrepresentation of Elderly People in Randomised Controlled Trials. The Example of Trials of 4 Widely Prescribed Drugs , 2012, PloS one.
[52] Gordon H Guyatt,et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review , 2012, BMJ : British Medical Journal.
[53] T. Jefferson,et al. Rethinking credible evidence synthesis , 2012, BMJ : British Medical Journal.
[54] A. Smyth,et al. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study , 2012, BMJ : British Medical Journal.
[55] Lisa Bero,et al. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses , 2012, BMJ : British Medical Journal.
[56] A. Hollis,et al. Comment on “The economics of follow-on drug research and development: Trends in entry rates and the timing of development” , 2012, PharmacoEconomics.
[57] V. Montori,et al. The idolatry of the surrogate , 2011, BMJ : British Medical Journal.
[58] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[59] Salomeh Keyhani,et al. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study , 2011, BMJ : British Medical Journal.
[60] Vinay Prasad,et al. The frequency of medical reversal. , 2011, Archives of internal medicine.
[61] John P A Ioannidis,et al. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. , 2011, Journal of clinical epidemiology.
[62] J. Ioannidis,et al. Magnitude of effects in clinical trials published in high-impact general medical journals. , 2011, International journal of epidemiology.
[63] J. Ioannidis,et al. Public Availability of Published Research Data in High-Impact Journals , 2011, PloS one.
[64] C. Furberg,et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.
[65] J. Cylus,et al. Evidence of Comparative Efficacy Should Have a Formal Role in European Drug Approvals Article (published Version) (refereed) , 2022 .
[66] Malcolm Rowland,et al. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response , 2011, Nature Reviews Drug Discovery.
[67] J. Ioannidis,et al. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.
[68] P. Gøtzsche,et al. Opening up data at the European Medicines Agency , 2011, BMJ : British Medical Journal.
[69] Mary K. Kowal,et al. Availability of comparative efficacy data at the time of drug approval in the United States. , 2011, JAMA.
[70] Eric G Campbell,et al. Conflicts of interest in cardiovascular clinical practice guidelines. , 2011, Archives of internal medicine.
[71] Nicholas C. Ide,et al. The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.
[72] Ian F Tannock,et al. When are "positive" clinical trials in oncology truly positive? , 2011, Journal of the National Cancer Institute.
[73] S. Goodman,et al. A Systematic Examination of the Citation of Prior Research in Reports of Randomized, Controlled Trials , 2011, Annals of Internal Medicine.
[74] D. Eyding,et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.
[75] J. Ioannidis,et al. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence , 2010, BMJ : British Medical Journal.
[76] D. Cohen. Rosiglitazone: what went wrong? , 2010, BMJ : British Medical Journal.
[77] Alexander J Sutton,et al. Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. , 2010, Journal of clinical epidemiology.
[78] Douglas G Altman,et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. , 2010, JAMA.
[79] R. Frank,et al. The Rise and Fall of Gabapentin for Bipolar Disorder: A Case Study on Off-Label Pharmaceutical Diffusion , 2010, Medical care.
[80] G. Guyatt,et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. , 2010, JAMA.
[81] D. McCormick,et al. Characteristics of published comparative effectiveness studies of medications. , 2010, JAMA.
[82] Douglas G Altman,et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews , 2010, BMJ : British Medical Journal.
[83] J. Ioannidis,et al. Industry sponsorship and selection of comparators in randomized clinical trials , 2010, European journal of clinical investigation.
[84] F. Song,et al. Dissemination and publication of research findings: an updated review of related biases. , 2010, Health technology assessment.
[85] E Ray Dorsey,et al. Funding of US biomedical research, 2003-2008. , 2010, JAMA.
[86] Kay Dickersin,et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. , 2009, The New England journal of medicine.
[87] Philip W. Lavori,et al. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. , 2009, The New England journal of medicine.
[88] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[89] J. Ioannidis,et al. The elderly were under-represented in osteoarthritis clinical trials. , 2009, Journal of clinical epidemiology.
[90] John P A Ioannidis,et al. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. , 2009, Archives of internal medicine.
[91] Isabelle Boutron,et al. Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.
[92] S. Paisley,et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials , 2009, Journal of internal medicine.
[93] R. Centor,et al. Reassessment of clinical practice guidelines: go gently into that good night. , 2009, JAMA.
[94] R. Califf,et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. , 2009, JAMA.
[95] E. Douglass. The ADVANTAGE Seeding Trial: A Review of Internal Documents , 2009 .
[96] P. Glasziou,et al. Avoidable waste in the production and reporting of evidence , 2009 .
[97] Lisa Bero,et al. Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation , 2008, PLoS medicine.
[98] H. Leufkens,et al. Choice of Comparator in Active Control Trials of New Drugs , 2008, The Annals of pharmacotherapy.
[99] P. Rochon,et al. Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. , 2008, Journal of clinical epidemiology.
[100] Allen D. Roses,et al. Pharmacogenetics in drug discovery and development: a translational perspective , 2008, Nature Reviews Drug Discovery.
[101] Peter C Gøtzsche,et al. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support : Differences in methodological quality and conclusions , 2015 .
[102] John P A Ioannidis,et al. Perfect study, poor evidence: interpretation of biases preceding study design. , 2008, Seminars in hematology.
[103] Carl Heneghan,et al. What is missing from descriptions of treatment in trials and reviews? , 2008, BMJ : British Medical Journal.
[104] Sally Hopewell,et al. Reporting of adverse events in systematic reviews can be improved: survey results. , 2008, Journal of clinical epidemiology.
[105] S. Nissen. ENHANCE and ACCORD: Controversy over surrogate end points , 2008, Current cardiology reports.
[106] S. Sismondo. How Pharmaceutical Industry Funding Affects Trial Outcomes: Causal Structures and Responses , 2008, Social science & medicine.
[107] Allen J. Taylor,et al. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? , 2008, The New England journal of medicine.
[108] John Ioannidis,et al. Exploring the Geometry of Treatment Networks , 2008, Annals of Internal Medicine.
[109] Douglas G Altman,et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.
[110] Sergio Sismondo,et al. Pharmaceutical company funding and its consequences: a qualitative systematic review. , 2008, Contemporary clinical trials.
[111] Matthias Briel,et al. Early stopping of randomized clinical trials for overt efficacy is problematic. , 2008, Journal of clinical epidemiology.
[112] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[113] B. Thiers,et al. Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals: A Systematic Sampling Review , 2008 .
[114] J. Ioannidis,et al. Persistence of contradicted claims in the literature. , 2007, JAMA.
[115] Veronica Yank,et al. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study , 2007, BMJ : British Medical Journal.
[116] Allen F. Shaughnessy,et al. Clinical Epidemiology: A Basic Science for Clinical Medicine , 2007, BMJ : British Medical Journal.
[117] Peter C Gøtzsche,et al. Data extraction errors in meta-analyses that use standardized mean differences. , 2007, JAMA.
[118] Gordon H Guyatt,et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.
[119] H. Leufkens,et al. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. , 2007, British journal of clinical pharmacology.
[120] H. Yazici,et al. A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor α inhibitors , 2006, Annals of the rheumatic diseases.
[121] Peter C Gøtzsche,et al. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review , 2006, BMJ : British Medical Journal.
[122] M. Chren,et al. Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents , 2006, Annals of Internal Medicine.
[123] J. Ioannidis,et al. Origin and funding of the most frequently cited papers in medicine: database analysis , 2006, BMJ : British Medical Journal.
[124] L. Gluud. Bias in clinical intervention research. , 2006, American journal of epidemiology.
[125] R. Matthews,et al. What are the implications of optimism bias in clinical research? , 2006, The Lancet.
[126] Gordon H Guyatt,et al. Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.
[127] H. Rehman. Under-representation of the elderly in clinical trials. , 2005, European journal of internal medicine.
[128] J. Ioannidis. Contradicted and initially stronger effects in highly cited clinical research. , 2005, JAMA.
[129] Nicola J Cooper,et al. The use of systematic reviews when designing studies , 2005, Clinical trials.
[130] Thomas A Trikalinos,et al. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. , 2005, Journal of clinical epidemiology.
[131] J. Ioannidis,et al. Relative Citation Impact of Various Study Designs in the Health Sciences , 2005, JAMA.
[132] Richard Smith,et al. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies , 2005, PLoS medicine.
[133] Peter C Gøtzsche,et al. [Better reporting of harms in randomized trials: an extension of the CONSORT statement]. , 2005, Ugeskrift for laeger.
[134] F. Rockhold. The Society for Clinical Trials supports United States legislation mandating trials registration , 2005, Clinical trials.
[135] John Hoey,et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2005, Circulation.
[136] D. Altman,et al. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors , 2005, BMJ : British Medical Journal.
[137] R. Stafford,et al. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. , 2005, Archives of internal medicine.
[138] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[139] John Hoey,et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2004, JAMA.
[140] Thomas R Fleming,et al. Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.
[141] M. Egger,et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.
[142] Eric J Topol,et al. Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.
[143] J. Ioannidis,et al. Safety reporting in randomized trials of mental health interventions. , 2004, The American journal of psychiatry.
[144] A. Hrõbjartsson,et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.
[145] John Hoey,et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2004, JAMA.
[146] Andrew D Oxman,et al. HARLOT plc: an amalgamation of the world's two oldest professions , 2003, BMJ : British Medical Journal.
[147] D. Stryer,et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.
[148] R. Glasgow,et al. Why don't we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. , 2003, American journal of public health.
[149] B. Djulbegovic,et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.
[150] C. Gross,et al. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.
[151] Harlan M Krumholz,et al. Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.
[152] Ethan M Balk,et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. , 2002, JAMA.
[153] C. Gluud,et al. Citation bias of hepato-biliary randomized clinical trials. , 2002, Journal of clinical epidemiology.
[154] Christian Gluud,et al. Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses , 2001, Annals of Internal Medicine.
[155] E. Ernst,et al. Assessment of therapeutic safety in systematic reviews: literature review , 2001, BMJ : British Medical Journal.
[156] J. Ioannidis,et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. , 2001, JAMA.
[157] K. Alexander,et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. , 2001, JAMA.
[158] J. Ioannidis,et al. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.
[159] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[160] Gordon H. Guyatt,et al. Guides to the Medical Literature XXV . Evidence-Based Medicine : Principles for Applying the Users ’ Guides to Patient Care , 2000 .
[161] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[162] M. Mayo-Smith,et al. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. , 1999, JAMA.
[163] J. Grimshaw,et al. Potential benefits, limitations, and harms of clinical guidelines , 1999, BMJ.
[164] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[165] J. Ioannidis. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.
[166] D J Torgerson,et al. Pragmatic trials: lab meets bedside , 2019, The British journal of dermatology.
[167] S Garattini,et al. Are me-too drugs justified? , 1997, Journal of nephrology.
[168] R. Simes,et al. Publication bias: evidence of delayed publication in a cohort study of clinical research projects , 1997, BMJ.
[169] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[170] J. Grimshaw,et al. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations , 1993, The Lancet.
[171] I Chalmers,et al. Underreporting research is scientific misconduct. , 1990, JAMA.
[172] P. Gøtzsche. Reference bias in reports of drug trials. , 1987, British medical journal.